Sepsis-Associated Acute Kidney Injury

Cross-source consensus on Sepsis-Associated Acute Kidney Injury from 1 sources and 3 claims.

1 sources · 3 claims

Risks & contraindications

Current treatment for sepsis-associated acute kidney injury is supportive because no specific pharmacological intervention exists. — Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a p
Sepsis-associated acute kidney injury is common among critically ill patients and is associated with progression to chronic kidney disease and death. — Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a p
A substantial proportion of patients with sepsis-associated acute kidney injury require renal replacement therapy. — Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a p